|
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Clinical research trials and Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter. Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter  Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
For Condition: Leukemia,Cervical Cancer,Multiple Myeloma,Lymphoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications. PURPOSE: Randomized phase III trial to determine the effectiveness of dalteparin in preventing catheter-related complications in cancer patients who are receiving chemotherapy through a catheter.
Details: OBJECTIVES: I. Determine if dalteparin will reduce the incidence of clinically significant catheter related complications (i.e., asymptomatic catheter related thrombosis) in cancer patients receiving chemotherapy through a central venous catheter. PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are stratified according to treatment center and catheter placement (proximal to axilla vs distal to axilla). Patients are randomized to one of two treatment arms. Arm I: Patients receive dalteparin subcutaneously (SC) daily. Arm II: Patients receive placebo SC daily. Treatment continues for 16 weeks or until catheter removal in the absence of unacceptable toxicity. Patients are followed for 30 days. PROJECTED ACCRUAL: A total of 345 patients (230 in arm I and 115 in arm II) will be accrued for this study over 6 months.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed malignancy - No more than 5 days since placement of central venous catheter for administration of chemotherapy; Expected length of catheter use at least 16 weeks --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent high dose chemotherapy with stem cell transplantation - Chemotherapy: See Disease Characteristics; No concurrent induction/consolidation chemotherapy for leukemia; No concurrent high dose chemotherapy with stem cell transplantation - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: At least 3 months since prior eye, ear, or CNS surgery - Other: At least 30 days since prior aspirin, dipyridamole, unfractionated heparin, other low molecular weight heparins, or other anticoagulation therapy (except heparin flushing) --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 16 weeks - Hematopoietic: Platelet count at least 100,000/mm3; Absolute neutrophil count at least 1,500/mm3; No known coagulopathy - Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) except in case of Gilbert's syndrome; AST no greater than 3 times ULN (no greater than 5 times ULN in case of liver metastases); PT/PTT no greater than 1.5 times ULN - Renal: Creatinine no greater than 2 times ULN - Cardiovascular: No uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure; No myocardial infarction in past 6 months; No uncontrolled cardiac arrhythmia - Other: No known hypersensitivity (including heparin induced thrombocytopenia) to dalteparin, heparin, or other low molecular weight heparins; No active uncontrolled infection, including existing catheter related infection; HIV negative; No CNS trauma in past 3 months; No retinal detachment in past 6 months; No mental incapacitation or psychiatric illness that would preclude study; No other serious concurrent disease that would preclude study; No active gastrointestinal or genitourinary tract bleeding; No intracranial or intraocular hemorrhage in past year; Must weigh at least 90 pounds
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JohnGlaspy, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068075; P-UPJOHN-98-FRAG-076,UCLA-9910055,NCI-G00-1822
Study Start Date: October 2000
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006083
Other Leukemia Studies:
1. Phase I Study of Anti-Tac(Fv)-PE38 (LMB-2), a Recombinant Single-Chain Immunotoxin for Treatment of Tac-Expressing Malignancies
2. Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
3. Epoetin alfa in Treating Anemia in Patients With Solid Tumors
4. UCN-01 and Fludarabine to Treat Lymphoma and Leukemia
5. 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Related Studies:
Other Leukemia Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
|
|
|
|
|
|
|
|
